[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620904":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":51,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Bakirkoy Dr. Sadi Konuk Research and Training Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group DR: Dexmedetomidine + Remifentanil","ACTIVE_COMPARATOR","The investigators will administer dexmedetomidine combined with remifentanil for anesthesia maintenance in this patient group.",[13],"Drug: Dexmedetomidine + Remifentanil",{"label":15,"type":10,"description":16,"interventionNames":17},"Group IR: Desflurane + Remifentanil","The investigators will administer desflurane combined with remifentanil for general anesthesia maintenance in this group.",[18],"Drug: Desflurane + Remifentanil",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dexmedetomidine + Remifentanil","Anesthesia Protocol\n\nAll patients will receive the same standardized induction regimen consisting of fentanyl (1 μg\u002Fkg), propofol (1 mg\u002Fkg), and rocuronium (0.5 mg\u002Fkg). Following induction, maintenance of general anesthesia will differ according to group allocation:\n\nIn Group DR, anesthesia maintenance will be provided with dexmedetomidine administered as a continuous infusion without a loading dose, combined with remifentanil infusion.\n\nRemifentanil infusion rates will be adjusted as clinically required to maintain adequate hemodynamic stability and surgical anesthesia depth",[9],null,{"type":21,"name":27,"description":16,"armGroupLabels":28,"otherNames":25},"Desflurane + Remifentanil",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"NALAN SAYGİ EMİR","CONTACT","00905422363672","nasaemir@hotmail.com",[36],{"facility":37,"status":38,"city":39,"state":39,"zip":40,"country":41,"countryCode":25,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Bakirkoy dr. Sadi Konuk","RECRUITING","Istanbul","34140","Turkey (Türkiye)",{"type":43,"coordinates":44},"Point",[45,46],28.94966,41.01384,{"lat":46,"lon":45},[49],{"name":50,"role":32,"phone":25,"phoneExt":25,"email":25},"Nalan Saygi Emir",{"type":52,"investigatorFullName":50,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Specialist Physician","100620904","inhalational-agents-versus-dexmedetomidine-for-maintenance-of-general-anesthesia-100620904",false,"NCT07363681","Inhalational Agents Versus Dexmedetomidine for Maintenance of General Anesthesia","Beyond Inhalational Agents: Dexmedetomidine for Maintenance of General Anesthesia - A Prospective Randomized Clinical Trial","Inclusion Criteria\n\n* Age ≥ 39 years\n* Classified as ASA physical status II-IV\n* Scheduled for elective endoscopic urological surgery (e.g., URS, TUR-B, PCNL, TUR-P)\n* Scheduled for postoperative follow-up in the Post-Anesthesia Care Unit (PACU)\n* Ability to provide written informed consent\n\nExclusion Criteria\n\n* Requirement for conversion to open surgery during the perioperative period\n* Patients who decline to participate in the study\n* Presence of neuropsychiatric disorders (e.g., dementia, Parkinson's disease, epilepsy, or history of head trauma)\n* History of alcohol or substance abuse\n* Use of psychoactive medications\n* Inability to communicate adequately for any reason",true,"ALL","39 Years","99 Years",{"count":66,"type":67},150,"ESTIMATED","INTERVENTIONAL",[70],"NA","The climate crisis and environmental pollution are escalating day by day, making the reduction of carbon footprints increasingly important both on an individual and industrial level. Inhalational anesthetic agents are widely used in daily anesthesia practice. However, some of these agents are released into the environment either unchanged or as metabolic by-products. It can take hundreds of years for these substances to be fully eliminated from nature. Therefore, there is a growing interest in identifying alternative anesthetic agents that are fully metabolized, do not produce waste, have a shorter duration of action, and pose less harm to ecosystems.\n\nRecent clinical studies have shown that dexmedetomidine, when administered intraoperatively via infusion without a loading dose and in combination with inhalational agents, provides more stable hemodynamics and results in a shorter postoperative recovery period. Commonly used as a long-term sedative agent in intensive care units, dexmedetomidine has gained popularity in the intraoperative setting due to its stable hemodynamic profile, low incidence of withdrawal symptoms, and faster recovery.\n\nIn this study, it is aimed to demonstrate the potential use of dexmedetomidine-whose pharmacodynamic and pharmacokinetic properties are well-known to experienced anesthesiologists-as an alternative to inhalational anesthetic agents for the maintenance of anesthesia, particularly in the geriatric patient population.",[73,74,75,76],"Ureterorenoscopic Lithotripsy","Transurethral Resection of the Bladder","Percutaneous Nephrolithotomy","Transurethral Resection of the Prostate","2026-01-15",{"date":79,"type":80},"2026-01-23","ACTUAL",{"date":82,"type":80},"2024-10-01",{"date":84,"type":67},"2026-03-09",{"name":5,"class":6},1]